Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for so...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, An-Liang, Wang, Xiao-Chen, Lu, Yi-Jun, Lu, Xiao-Jie, Sun, Beicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685771/
https://www.ncbi.nlm.nih.gov/pubmed/29163850
http://dx.doi.org/10.18632/oncotarget.19361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685771/
https://www.ncbi.nlm.nih.gov/pubmed/29163850
http://dx.doi.org/10.18632/oncotarget.19361

Ejemplares similares